Total Payments
$18,836
2023 Payments
$2,650
Companies
5
Transactions
39
Payment Breakdown by Category
Other$9,319 (49.5%)
Consulting$6,863 (36.4%)
Research$2,650 (14.1%)
Education$3.79 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $6,863 | 14 | 36.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,750 | 11 | 35.8% |
| Unspecified | $2,650 | 11 | 14.1% |
| Grant | $2,569 | 2 | 13.6% |
| Education | $3.79 | 1 | 0.0% |
Payments by Type
General
$16,185
28 transactions
Research
$2,650
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $13,613 | 25 | $0 (2021) |
| AbbVie, Inc. | $2,569 | 2 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $1,347 | 1 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,303 | 10 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $2,650 | 11 | E.R. Squibb & Sons, L.L.C. ($1,347) |
| 2021 | $2,363 | 4 | Allergan, Inc. ($2,363) |
| 2020 | $2,700 | 6 | Allergan, Inc. ($2,700) |
| 2019 | $1,800 | 4 | Allergan Inc. ($1,800) |
| 2018 | $3,825 | 7 | Allergan Inc. ($3,825) |
| 2017 | $5,498 | 7 | Allergan Inc. ($2,925) |
All Payment Transactions
39 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/22/2023 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | — | Cash or cash equivalent | $1,347.37 | Research |
| Study: A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy • Category: Neuroscience | ||||||
| 02/03/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | In-kind items and services | $147.70 | Research |
| Study: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) | ||||||
| 01/25/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | In-kind items and services | $537.53 | Research |
| Study: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) | ||||||
| 01/25/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | In-kind items and services | $71.75 | Research |
| Study: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) | ||||||
| 01/25/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | In-kind items and services | $58.40 | Research |
| Study: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) | ||||||
| 01/25/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | In-kind items and services | $46.55 | Research |
| Study: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) | ||||||
| 01/25/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | In-kind items and services | $32.99 | Research |
| Study: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) | ||||||
| 01/25/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | In-kind items and services | $19.28 | Research |
| Study: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) | ||||||
| 01/25/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | In-kind items and services | $18.61 | Research |
| Study: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) | ||||||
| 01/24/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | In-kind items and services | $188.12 | Research |
| Study: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) | ||||||
| 01/24/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | In-kind items and services | $182.11 | Research |
| Study: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) | ||||||
| 05/11/2021 | Allergan, Inc. | — | Consulting Fee | Cash or cash equivalent | $562.50 | General |
| 05/05/2021 | Allergan, Inc. | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 05/05/2021 | Allergan, Inc. | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 04/15/2021 | Allergan, Inc. | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| 10/14/2020 | Allergan, Inc. | LINZESS (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/31/2020 | Allergan, Inc. | LINZESS (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/31/2020 | Allergan, Inc. | LINZESS (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/22/2020 | Allergan, Inc. | LINZESS (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/26/2020 | Allergan, Inc. | LINZESS (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/09/2020 | Allergan, Inc. | VIBERZI (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/16/2019 | Allergan Inc. | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| 06/27/2019 | Allergan Inc. | LINZESS (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/14/2019 | Allergan Inc. | LINZESS (Drug) | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/14/2019 | Allergan Inc. | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy | E.R. Squibb & Sons, L.L.C. | $1,347 | 1 |
| A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) | Takeda Pharmaceuticals U.S.A., Inc. | $1,303 | 10 |
About Dr. Michael Stephens, MD
Dr. Michael Stephens, MD is a Pediatric Gastroenterology healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1932153830.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Stephens, MD has received a total of $18,836 in payments from pharmaceutical and medical device companies, with $2,650 received in 2023. These payments were reported across 39 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($6,863).
Ad
Practice Information
- Specialty Pediatric Gastroenterology
- Other Specialties Pediatric Gastroenterology, Pediatric Gastroenterology
- Location Rochester, MN
- Active Since 05/22/2006
- Last Updated 08/20/2020
- Taxonomy Code 2080P0206X
- Entity Type Individual
- NPI Number 1932153830
Products in Payments
- LINZESS (Drug) $7,200
- ZEPOSIA (Drug) $1,347
- VIBERZI (Drug) $450.00
- (820) Cholbam (Drug) $3.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Gastroenterology Doctors in Rochester
Dr. Sara Hassan, M.d, M.D
Pediatric Gastroenterology — Payments: $3,424
Pediatric Gastroenterology $3,424
Mhd Louai Manini, Md, MD
Pediatric Gastroenterology — Payments: $1,172
Pediatric Gastroenterology $1,172
Dr. Megan Gabel, Md, MD
Pediatric Gastroenterology — Payments: $631.64
Pediatric Gastroenterology $631.64
Ajay Rana, Md, MD
Pediatric Gastroenterology — Payments: $497.80
Pediatric Gastroenterology $497.80
Dr. Esther Prince, Md, MD
Pediatric Gastroenterology — Payments: $468.97
Pediatric Gastroenterology $468.97
Dr. Marilyn Brown, Md, MD
Pediatric Gastroenterology — Payments: $214.84
Pediatric Gastroenterology $214.84